The company polled hundreds of orthopedic surgeons from a total of 37 countries.
Here are four findings:
1. The majority of respondents said that they are more inclined to administer single-injection hyaluronic acid viscosupplementation treatments rather than the three- or five-dose cycle injection treatments.
2. For single-injection HA treatments, the physicians reported they most often used Synvisc by Genzyme.
3. For total knee replacement procedures, physicians said they preferred implants from DePuy Synthes and Zimmer Biomet.
4. Each physician surveyed saw an average of 30 patients per week.
More articles on devices:
Dr. Nicole Ehrhart’s preclinical study affirms AlloStem Cellular Bone Allograft effectiveness: 5 key takeaways
Safe Orthopaedics names Pierre Dumouchel CEO: 3 things to know
Aurora Spine receives $1M insider loan: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
